In vitro activities of ertapenem against drug-resistant Streptococcus pneumoniae and other respiratory pathogens from 12 Asian countries

In vitro activities of ertapenem and 11 other comparator agents were tested against 1025 isolates of respiratory pathogens collected from 12 Asian countries. Resistance rate to ertapenem was 1.2% in 602 isolates of Streptococcus pneumoniae (MIC50, 0.06/MIC90, 1 μg/mL). Ertapenem was also very active against penicillin-, ciprofloxacin-, erythromycin-, and multidrug-resistant pneumococcal isolates (resistance rate: 3.5%, 2.7%, 1.9%, and 2.7%, respectively). Ertapenem-resistant pneumococcal isolates were found only in Vietnam and Korea. Ertapenem resistance was not found in methicillin-susceptible Staphylococcus aureus, Haemophilus influenzae, Moraxella catarrhalis, and Klebsiella pneumoniae, including extended-spectrum β-lactamase producers. In vitro data suggest that ertapenem could be a useful treatment option for community-acquired pneumonia.